Literature DB >> 1644189

Site-directed mutagenesis of a single residue changes the binding properties of the serotonin 5-HT2 receptor from a human to a rat pharmacology.

H T Kao1, N Adham, M A Olsen, R L Weinshank, T A Branchek, P R Hartig.   

Abstract

Mesulergine displays approximately 50-fold higher affinity for the rat 5-HT2 receptor than for the human receptor. Comparison of the deduced amino acid sequences of cDNA clones encoding the human and rat 5-HT2 receptors reveals only 3 amino acid differences in their transmembrane domains. Only one of these differences (Ser----Ala at position 242 of TM5) is near to regions implicated in ligand binding by G protein-coupled receptors. We investigated the effect of mutating Ser242 of the human 5-HT2 receptor to an Ala residue as is found in the rat clone. Both [3H]mesulergine binding and mesulergine competition of [3H]ketanserin binding showed high affinity for rat membranes and the mutant human clone but low affinity for the native human clone, in agreement with previous studies of human postmortem tissue. These studies suggest that a single naturally occurring amino acid change between the human and the rat 5-HT2 receptors makes a major contribution to their pharmacological differences.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1644189     DOI: 10.1016/0014-5793(92)80705-l

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  12 in total

1.  Molecular Architecture of G Protein-Coupled Receptors.

Authors:  A Michiel van Rhee; Kenneth A Jacobson
Journal:  Drug Dev Res       Date:  1996-01-01       Impact factor: 4.360

2.  Pharmacological and behavioral characterization of the 5-HT2A receptor in C57BL/6N mice.

Authors:  John P Dougherty; Vincent J Aloyo
Journal:  Psychopharmacology (Berl)       Date:  2011-02-22       Impact factor: 4.530

3.  Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation.

Authors:  M Ruat; E Traiffort; R Leurs; J Tardivel-Lacombe; J Diaz; J M Arrang; J C Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

Review 4.  Integration of animal pharmacokinetic and pharmacodynamic data in drug safety assessment.

Authors:  D A Smith
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jan-Mar       Impact factor: 2.441

Review 5.  Drug toxicokinetics: scope and limitations that arise from species differences in pharmacodynamic and carcinogenic responses.

Authors:  A Monro
Journal:  J Pharmacokinet Biopharm       Date:  1994-02

6.  Differential pharmacology between the guinea-pig and the gorilla 5-HT1D receptor as probed with isochromans (5-HT1D-selective ligands).

Authors:  J F Pregenzer; G L Alberts; W B Im; J L Slightom; M D Ennis; R L Hoffman; N B Ghazal; R E TenBrink
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

7.  Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs.

Authors:  Landon M Klein; Nicholas V Cozzi; Paul F Daley; Simon D Brandt; Adam L Halberstadt
Journal:  Neuropharmacology       Date:  2018-02-27       Impact factor: 5.250

8.  International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors.

Authors:  Margarita L Dubocovich; Philippe Delagrange; Diana N Krause; David Sugden; Daniel P Cardinali; James Olcese
Journal:  Pharmacol Rev       Date:  2010-07-06       Impact factor: 25.468

9.  The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors.

Authors:  D W Bonhaus; C Bach; A DeSouza; F H Salazar; B D Matsuoka; P Zuppan; H W Chan; R M Eglen
Journal:  Br J Pharmacol       Date:  1995-06       Impact factor: 8.739

10.  Molecular pharmacology and ligand docking studies reveal a single amino acid difference between mouse and human serotonin 5-HT2A receptors that impacts behavioral translation of novel 4-phenyl-2-dimethylaminotetralin ligands.

Authors:  Clinton E Canal; Tania Cordova-Sintjago; Yue Liu; Myong S Kim; Drake Morgan; Raymond G Booth
Journal:  J Pharmacol Exp Ther       Date:  2013-09-30       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.